Advancing RNA liquid biopsy via nanopore sequencing

Webinar Overview

RNA liquid biopsies enable minimally invasive systemic profiling of tissues and organs through cell-free RNAs present in the blood. In this study, nanopore sequencing revealed thousands of full-length cell-free RNAs in pancreatic and esophageal cancer patients.

Using COMPLETE-seq technology, high levels of repetitive cell-free RNAs, particularly SINE-derived RNAs, were detected in pancreatic cancer patients. These repetitive cell-free RNA features improved the performance of machine-learning models for cancer classification.

Importantly, nanopore sequencing uncovered over 250,000 novel cell-free RNAs, highlighting the potential of long-read sequencing for identifying novel biomarkers of health and disease.

Viewers of this webinar learned:

• RNA liquid biopsy technology enables highly sensitive and specific cancer detection in a minimally invasive way

• Repetitive cell-free RNAs are enriched in cancer patients and can be leveraged to improve disease classification

• Nanopore sequencing reveals full-length cell-free RNAs, including thousands of novel and disease-specific RNAs